Chardan NEXTECH Acquisition and Recent Analyst Coverage
Chardan NEXTECH Acquisition (NASDAQ: CHARDAN) is a publicly traded biotechnology company listed on the New York Stock Exchange with its financial reporting conducted in U.S. dollars.
Key Recent Developments
| Date | Source | Event |
|---|---|---|
| 2026‑10‑20 17:58 | de.investing.com | Chardan NEXTECH Acquisition highlights a financing shortfall in the OSE Immunotherapeutics program presented at the 10th Annual Healthcare Conference. The conference also showcased clinical progress within the same program. |
| 2026‑10‑20 17:34 | de.investing.com | Healios presentation at the 10th Chardan Healthcare Conference emphasized expansion into the Japanese market and scaling of production capabilities. |
| 2026‑10‑20 11:54 | www.investing.com | Tvardi Therapeutics initiates coverage with a buy recommendation on the STAT3 platform, signaling renewed interest in Chardan’s pipeline. |
| 2026‑10‑19 13:34 | feeds.feedburner.com | MNKD initiates coverage on Chardan Capital, announcing a price target of $10.00. |
| 2026‑10‑19 13:06 | www.investing.com | MannKind initiates coverage of Chardan Capital with a buy rating focused on the company’s pipeline. |
Analyst Sentiment
- MNKD: Buy rating; $10.00 price target.
- MannKind: Buy rating; emphasis on pipeline assets.
- Tvardi Therapeutics: Buy recommendation on STAT3 platform.
Conference Highlights
- The 10th Annual Healthcare Conference provided a platform for Chardan to discuss ongoing clinical programs, particularly OSE Immunotherapeutics, despite a noted financing gap.
- Healios’ presentation underscored strategic moves toward the Japanese market and production scale‑up, aligning with Chardan’s broader commercialization strategy.
Implications for Investors
The convergence of analyst buy ratings and active conference presentations suggests sustained institutional interest in Chardan NEXTECH Acquisition’s therapeutic pipeline and market expansion initiatives. Investors should monitor the company’s financing activities, clinical milestones, and regulatory approvals that may influence the stock’s valuation relative to the analysts’ price targets.
